Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 11/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 9/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604867 | 1.00 | ALOX5 (0.52) | ALOX5PTGS1PTGS2MAOBATG4B | |
| SCHEMBL3608669 | 0.77 | MAOB (0.47) | ALOX5PTGS1PTGS2MAOBTDP1 | |
| SCHEMBL3608672 | 0.77 | MAOB (0.47) | ALOX5PTGS1PTGS2MAOBTDP1 | |
| SCHEMBL3596089 | 0.76 | PTGS1 (0.57) | ALOX5PTGS1PTGS2MAOBTDP1 | |
| SCHEMBL13316587 | 0.71 | MAOB (0.45) | ALOX5PTGS1PTGS2MAOB | |
| SCHEMBL9729787 | 0.68 | ALOX5 (1.00) | ALOX5PTGS1PTGS2 | |
| SCHEMBL10625566 | 0.68 | KDM4E (0.48) | ATG4BPLA2G1BTHRATHRBCYP1A2 | |
| SCHEMBL7605456 | 0.66 | ALOX5 (0.51) | ALOX5PTGS1PTGS2THRATHRB | |
| SCHEMBL3596696 | 0.65 | PTGS1 (0.44) | ALOX5PTGS1PTGS2TDP1 | |
| SCHEMBL3596693 | 0.65 | PTGS1 (0.44) | ALOX5PTGS1PTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | BOIZEL ROBERT | 2010-06-24 | — | — | US | claimed |
| US-20070099854-A1 | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | claimed |
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | BOIZEL ROBERT | 2010-06-24 | — | — | US | disclosed |
| US-20070099854-A1 | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099854-A1 | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | XDH, URB2, ALOX12 | ALOX5 7/4885PTGS1 116/4885PTGS2 252/4885 |
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | XDH, URB2, ALOX12 | ALOX5 7/4885PTGS1 116/4885PTGS2 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.